HAIER BIOMEDICAL(688139)2024-12-13 08:35Group 1: Company Growth and Industry Position - The non-storage new industry contributed 45% to revenue in the first three quarters, with a year-on-year growth of 21% [3] - The company maintains a strong growth momentum with a quarterly growth rate of around 20% in the third quarter [3] - The company focuses on life sciences and medical innovation, enhancing its product series and expanding through acquisitions [3] Group 2: Acquisition Strategy - Future acquisitions will target high-tech companies in the blood and laboratory sectors to strengthen core business [4] - The company’s acquisition actions aim for long-term strategic goals rather than short-term profit [4] - The plasma collection business acquired in 2020 has shown a compound annual growth rate of approximately 14% over four years [3] Group 3: International Market Performance - Overseas market revenue increased by 13.36% year-on-year and 40.09% quarter-on-quarter [5] - The overseas distribution network has expanded to over 800 partners, covering key global markets [5] - The company has established long-term partnerships with WHO and UNICEF, with products and services available in nearly 150 countries [5] Group 4: Shareholder Returns - The company has implemented a three-year shareholder dividend plan (2023-2025) to protect investor interests, especially for small shareholders [6] - Cumulative dividends since listing amount to 641 million RMB, with a cash dividend compound growth rate close to 30% [6] - The cash dividend rate for 2023 reached 40%, and the company has initiated a new share buyback plan [6]